$103.00
0.700.68%
At close: -
$103.00
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Encompass Health Analyst Ratings and Price Targets | NYSE:EHC | Benzinga
Encompass Health Corp has a consensus price target of $90.76 based on the ratings of 17 analysts. The high is $120 issued by Keybanc on February 10, 2025. The low is $57 issued by Barclays on March 14, 2023. The 3 most-recent analyst ratings were released by RBC Capital, Keybanc, and Barclays on February 11, 2025, February 10, 2025, and February 7, 2025, respectively. With an average price target of $116 between RBC Capital, Keybanc, and Barclays, there's an implied 12.62% upside for Encompass Health Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Keybanc
Barclays
Truist Securities
UBS
1calculated from analyst ratings
Analyst Ratings for Encompass Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/11/2025 | Buy Now | 6.8% | RBC Capital | Ben Hendrix61% | $110 → $110 | Reiterates | Outperform → Outperform | Get Alert |
| 02/10/2025 | Buy Now | 16.5% | Keybanc | Matthew Gillmor67% | $117 → $120 | Maintains | Overweight | Get Alert |
| 02/07/2025 | Buy Now | 14.56% | Barclays | Andrew Mok57% | $116 → $118 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | 6.8% | RBC Capital | Ben Hendrix61% | $105 → $110 | Maintains | Outperform | Get Alert |
| 10/30/2024 | Buy Now | 12.62% | Truist Securities | David Macdonald69% | $108 → $116 | Reiterates | Buy → Buy | Get Alert |
| 10/29/2024 | Buy Now | 12.62% | Barclays | Andrew Mok57% | $109 → $116 | Maintains | Overweight | Get Alert |
| 10/29/2024 | Buy Now | 13.59% | Keybanc | Matthew Gillmor67% | $115 → $117 | Maintains | Overweight | Get Alert |
| 10/14/2024 | Buy Now | 4.85% | Truist Securities | David Macdonald69% | $104 → $108 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | 11.65% | Keybanc | Matthew Gillmor67% | → $115 | Initiates | → Overweight | Get Alert |
| 09/26/2024 | Buy Now | 1.94% | RBC Capital | Ben Hendrix61% | $95 → $105 | Maintains | Outperform | Get Alert |
| 09/25/2024 | Buy Now | 6.8% | UBS | Andrew Mok57% | $100 → $110 | Maintains | Buy | Get Alert |
| 08/15/2024 | Buy Now | 0.97% | Truist Securities | David Macdonald69% | $100 → $104 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | -2.91% | UBS | Andrew Mok57% | $96 → $100 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 1.94% | Stephens & Co. | Scott Fidel71% | $105 → $105 | Reiterates | Overweight → Overweight | Get Alert |
| 08/06/2024 | Buy Now | 5.83% | Barclays | Andrew Mok57% | $113 → $109 | Maintains | Overweight | Get Alert |
| 07/15/2024 | Buy Now | -2.91% | Truist Securities | David Macdonald69% | $95 → $100 | Maintains | Buy | Get Alert |
| 07/10/2024 | Buy Now | 9.71% | Barclays | Andrew Mok57% | $108 → $113 | Maintains | Overweight | Get Alert |
| 07/10/2024 | Buy Now | -2.91% | Leerink Partners | Whit Mayo67% | → $100 | Initiates | → Outperform | Get Alert |
| 06/05/2024 | Buy Now | -8.74% | Stephens & Co. | Scott Fidel71% | $94 → $94 | Reiterates | Overweight → Overweight | Get Alert |
| 05/22/2024 | Buy Now | -7.77% | RBC Capital | Ben Hendrix61% | $83 → $95 | Maintains | Outperform | Get Alert |
| 04/26/2024 | Buy Now | -7.77% | Raymond James | John Ransom76% | $85 → $95 | Reiterates | Strong Buy → Strong Buy | Get Alert |
| 04/25/2024 | Buy Now | 4.85% | Barclays | Andrew Mok57% | $101 → $108 | Maintains | Overweight | Get Alert |
| 04/25/2024 | Buy Now | -7.77% | Mizuho | Ann Hynes86% | $93 → $95 | Maintains | Buy | Get Alert |
| 03/28/2024 | Buy Now | -1.94% | Barclays | Andrew Mok57% | $95 → $101 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | -7.77% | Barclays | Andrew Mok57% | → $95 | Initiates | → Overweight | Get Alert |
| 02/09/2024 | Buy Now | -19.42% | RBC Capital | Ben Hendrix61% | $83 → $83 | Reiterates | Outperform → Outperform | Get Alert |
| 02/09/2024 | Buy Now | -16.5% | Truist Securities | David Macdonald69% | $82 → $86 | Maintains | Buy | Get Alert |
| 02/09/2024 | Buy Now | -20.39% | Mizuho | Ann Hynes86% | $77 → $82 | Maintains | Buy | Get Alert |
| 01/16/2024 | Buy Now | -17.48% | Stephens & Co. | Scott Fidel71% | $85 → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 09/28/2023 | Buy Now | -19.42% | RBC Capital | Ben Hendrix61% | → $83 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2023 | Buy Now | -19.42% | RBC Capital | Ben Hendrix61% | $70 → $83 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | -32.04% | Barclays | Jason Goldberg55% | $61 → $70 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | -22.33% | Credit Suisse | Jonathan Yong65% | $76 → $80 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | -17.48% | Raymond James | John Ransom76% | $80 → $85 | Maintains | Strong Buy | Get Alert |
| 08/03/2023 | Buy Now | -20.39% | Truist Securities | David Macdonald69% | $75 → $82 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -25.24% | Mizuho | Ann Hynes86% | $74 → $77 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -31.07% | Barclays | Jason Goldberg55% | $61 → $71 | Maintains | Equal-Weight | Get Alert |
| 07/20/2023 | Buy Now | -24.27% | Stephens & Co. | Scott Fidel71% | → $78 | Reiterates | Overweight → Overweight | Get Alert |
| 06/29/2023 | Buy Now | -24.27% | Stephens & Co. | Scott Fidel71% | $74 → $78 | Maintains | Overweight | Get Alert |
| 05/02/2023 | Buy Now | -32.04% | RBC Capital | Ben Hendrix61% | $66 → $70 | Maintains | Outperform | Get Alert |
| 05/02/2023 | Buy Now | -22.33% | Raymond James | John Ransom76% | $72 → $80 | Maintains | Strong Buy | Get Alert |
| 05/01/2023 | Buy Now | -29.13% | Deutsche Bank | Pito Chickering67% | $70 → $73 | Maintains | Buy | Get Alert |
| 05/01/2023 | Buy Now | -28.16% | Stephens & Co. | Scott Fidel71% | $70 → $74 | Maintains | Overweight | Get Alert |
| 05/01/2023 | Buy Now | -26.21% | Credit Suisse | Jonathan Yong65% | $73 → $76 | Maintains | Outperform | Get Alert |
| 05/01/2023 | Buy Now | -28.16% | Mizuho | Ann Hynes86% | $69 → $74 | Maintains | Buy | Get Alert |
| 04/28/2023 | Buy Now | -28.16% | B of A Securities | Kevin Fischbeck68% | $69 → $74 | Maintains | Buy | Get Alert |
| 04/04/2023 | Buy Now | -40.78% | Barclays | Jason Goldberg55% | $57 → $61 | Maintains | Equal-Weight | Get Alert |
| 03/14/2023 | Buy Now | -44.66% | Barclays | Steve Valiquette54% | → $57 | Initiates | → Equal-Weight | Get Alert |
| 02/09/2023 | Buy Now | -27.18% | Truist Securities | David Macdonald69% | $70 → $75 | Maintains | Buy | Get Alert |
| 02/09/2023 | Buy Now | -29.13% | Credit Suisse | A.J. Rice70% | $62 → $73 | Maintains | Outperform | Get Alert |
| 02/09/2023 | Buy Now | -33.01% | Mizuho | Ann Hynes86% | $65 → $69 | Maintains | Buy | Get Alert |
| 02/08/2023 | Buy Now | -32.04% | Stephens & Co. | Scott Fidel71% | → $70 | Maintains | Overweight | Get Alert |
| 10/28/2022 | Buy Now | -43.69% | Stephens & Co. | Scott Fidel71% | $60 → $58 | Maintains | Overweight | Get Alert |
| 10/28/2022 | Buy Now | -30.1% | Raymond James | John Ransom76% | $65 → $72 | Maintains | Strong Buy | Get Alert |
| 09/21/2022 | Buy Now | -39.81% | Credit Suisse | A.J. Rice70% | $63 → $62 | Maintains | Outperform | Get Alert |
| 08/24/2022 | Buy Now | -35.92% | RBC Capital | Ben Hendrix61% | $82 → $66 | Maintains | Outperform | Get Alert |
| 08/08/2022 | Buy Now | -36.89% | Truist Securities | David Macdonald69% | $75 → $65 | Maintains | Buy | Get Alert |
| 08/04/2022 | Buy Now | -36.89% | BMO Capital | Matt Borsch77% | $83 → $65 | Maintains | Outperform | Get Alert |
| 08/04/2022 | Buy Now | -36.89% | Raymond James | John Ransom76% | $70 → $65 | Maintains | Strong Buy | Get Alert |
| 08/04/2022 | Buy Now | -38.83% | Barclays | Steve Valiquette54% | $80 → $63 | Maintains | Overweight | Get Alert |
| 06/21/2022 | Buy Now | -27.18% | Truist Securities | David Macdonald69% | $85 → $75 | Maintains | Buy | Get Alert |
| 06/21/2022 | Buy Now | -28.16% | Stephens & Co. | Scott Fidel71% | $78 → $74 | Maintains | Overweight | Get Alert |
| 06/17/2022 | Buy Now | -32.04% | Raymond James | John Ransom76% | $85 → $70 | Maintains | Strong Buy | Get Alert |
| 06/10/2022 | Buy Now | -20.39% | Credit Suisse | Nick Giovacchini51% | $83 → $82 | Maintains | Outperform | Get Alert |
| 06/08/2022 | Buy Now | -20.39% | RBC Capital | Ben Hendrix61% | $85 → $82 | Maintains | Outperform | Get Alert |
| 05/03/2022 | Buy Now | -17.48% | RBC Capital | Ben Hendrix61% | $104 → $85 | Maintains | Outperform | Get Alert |
| 05/02/2022 | Buy Now | -17.48% | Raymond James | John Ransom76% | $80 → $85 | Maintains | Strong Buy | Get Alert |
| 04/29/2022 | Buy Now | -19.42% | Credit Suisse | Jonathan Yong65% | $82 → $83 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Encompass Health (EHC) stock?
The latest price target for Encompass Health (NYSE:EHC) was reported by RBC Capital on February 11, 2025. The analyst firm set a price target for $110.00 expecting EHC to rise to within 12 months (a possible 6.80% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Encompass Health (EHC)?
The latest analyst rating for Encompass Health (NYSE:EHC) was provided by RBC Capital, and Encompass Health reiterated their outperform rating.
When was the last upgrade for Encompass Health (EHC)?
There is no last upgrade for Encompass Health
When was the last downgrade for Encompass Health (EHC)?
There is no last downgrade for Encompass Health.
When is the next analyst rating going to be posted or updated for Encompass Health (EHC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Encompass Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Encompass Health was filed on February 11, 2025 so you should expect the next rating to be made available sometime around February 11, 2026.
Is the Analyst Rating Encompass Health (EHC) correct?
While ratings are subjective and will change, the latest Encompass Health (EHC) rating was a reiterated with a price target of $110.00 to $110.00. The current price Encompass Health (EHC) is trading at is $103.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.